Literature DB >> 27113149

Multimorbidity in Older Adults with Atrial Fibrillation.

Michael A Chen1.   

Abstract

Older adults with atrial fibrillation often have multiple comorbid conditions, including common geriatric syndromes. Pharmacologic therapy, whether for rate control or rhythm control, can result in complications related to polypharmacy in patients who are often on multiple medications for other conditions. Because of uncertainty about the relative risks and benefits of rate versus rhythm control (including antiarrhythmic or ablation therapy), anticoagulation, and procedural treatments (eg, ablation, left atrial appendage closure, pacemaker placement) in older patients with multimorbidity, shared decision-making is essential. However, this may be challenging in patients with cognitive dysfunction, high fall risk, or advanced comorbidity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Geriatric syndromes; Multimorbidity; Older adults; Polypharmacy; Rate control; Rhythm control; Shared decision-making

Mesh:

Year:  2016        PMID: 27113149     DOI: 10.1016/j.cger.2016.01.001

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  7 in total

1.  Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation.

Authors:  J'Neka S Claxton; Alanna M Chamberlain; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Lindsay G S Bengtson; Alvaro Alonso
Journal:  Am J Med       Date:  2020-04-19       Impact factor: 4.965

2.  Atrial fibrillation in Mexican population: Differences in presentation, comorbidities and risk factors between men and women

Authors:  Humberto Rodríguez-Reyes; César I Laguna-Muñoz; Carlos F Gallegos-de Luna; Manuel O de-Los-Ríos-Ibarra; José L Salas-Pacheco; José L Leyva-Pons; Luz M Muñoz-Gutiérrez; Arturo Vargas-Hernandez; Karla M Rodríguez-Muñoz; Jaime Barragán-Luna; Marco A Alcocer-Gamba; Jorge Cortez-Lawrenz; Julio Farjat-Ruiz
Journal:  Arch Cardiol Mex       Date:  2022-07-01

3.  Multimorbidity: constellations of conditions across subgroups of midlife and older individuals, and related Medicare expenditures.

Authors:  Siran M Koroukian; Nicholas K Schiltz; David F Warner; Jiayang Sun; Kurt C Stange; Charles W Given; Avi Dor
Journal:  J Comorb       Date:  2017-04-10

4.  Integrated management of atrial fibrillation including tailoring of anticoagulation in primary care: study design of the ALL-IN cluster randomised trial.

Authors:  Carline J van den Dries; Ruud Oudega; Arif Elvan; Frans H Rutten; Sjef J C M van de Leur; Henk J G Bilo; Arno W Hoes; Karel G M Moons; Geert-Jan Geersing
Journal:  BMJ Open       Date:  2017-09-18       Impact factor: 2.692

5.  Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis.

Authors:  Celine Gallagher; Karin Nyfort-Hansen; Debra Rowett; Christopher X Wong; Melissa E Middeldorp; Rajiv Mahajan; Dennis H Lau; Prashanthan Sanders; Jeroen M Hendriks
Journal:  Open Heart       Date:  2020-04-06

6.  Impact of care coordination on oral anticoagulant therapy among patients with atrial fibrillation in routine clinical practice in Japan: a prospective, observational study.

Authors:  Fumiko Ono; Sayako Akiyama; Akifumi Suzuki; Yoshinobu Ikeda; Akira Takahashi; Hitoshi Matsuoka; Masahiro Sasaki; Tomonori Okamura; Nariaki Yoshihara
Journal:  BMC Cardiovasc Disord       Date:  2019-10-24       Impact factor: 2.298

7.  Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation.

Authors:  Frederik Dalgaard; Haolin Xu; Roland A Matsouaka; Andrea M Russo; Anne B Curtis; Peter Vibe Rasmussen; Martin H Ruwald; Gregg C Fonarow; Angela Lowenstern; Morten L Hansen; Jannik L Pallisgaard; Karen P Alexander; John H Alexander; Renato D Lopes; Christopher B Granger; William R Lewis; Jonathan P Piccini; Sana M Al-Khatib
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.